Enjoy complimentary customisation on priority with our Enterprise License!
Hurler Syndrome is an autosomal recessive disorder, which is caused by the mutation in the iduronidase (IDUA) gene. The two common types of mutation observed in the IDUA gene are W402X and Q70X, which consist of mutant alleles. Hurler syndrome is also referred to as mucopolysaccharidosis type I (MPS I), which happens when the body lacks the alpha-L-iduronidase enzyme, which is needed to break down long chains of sugar molecules. These chains of molecules are called glycosaminoglycans (GAGs). The bodies of people with this syndrome fail to produce an enzyme called Iysosomal alpha-L-iduronidase. As a result, in the absence of this enzyme, GAGs get accumulated significantly, which will damage the organs, including the heart. According to the NIH, approximately 1 in 100,000 newborns has severe Hurler syndrome. Such rising incidences of this syndrome are encouraging market players including Angiochem and ArmaGen are focusing on developing molecules for the treatment of neurological complications of lysosomal disorders, such as Hurler Syndrome and neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease, eventually, promoting the drug development for Hurler syndrome.
According to this pipeline analysis report, most of the drug development molecules in the pipeline are being developed for Hurler syndrome. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.
This pipeline analysis report provides a detailed analysis of the companies that are involved in the drug development for the treatment of Hurler syndrome. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are –
The intravenous route of administration (ROA) involves the application of the drug directly into the veins, which will have a more direct effect on the target cells.
According to this pipeline analysis report, the majority of the molecules that are currently in the drug development for hurler syndrome are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.
Technavio also offers customization on reports based on specific client requirement.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
PART 05: MAJOR REGULATORY AUTHORITIES
PART 06: PIPELINE LANDSCAPE
PART 07: COMPARATIVE ANALYSIS
PART 08: INDICATION ANALYSIS
PART 09: THERAPEUTIC ASSESSMENT (THERAPY BASED)
PART 10: THERAPEUTIC ASSESSMENT (ROA BASED)
PART 11: THERAPEUTIC ASSESSMENT BY TARGET
PART 12: KEY COMPANIES
PART 13: APPENDIX
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.